EUCTR2007-001412-23-DE进行中（未招募）1 期
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy Study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects may be included in the study if all of the following criteria are met. The subject must: 1. Have given written informed consent to participate in this study in accordance with local regulations 2. Have a confirmed diagnosis of cystic fibrosis 3. Be aged >= 6 years 4. Have FEV1 >=30 % and <90% predicted 5. Be able to perform all the techniques necessary to measure lung function.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are excluded from participating in this study if one or more of the following criteria are met. The subject must NOT: 1. Be investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted. 2. Be considered terminally ill” or listed for lung transplantation 3. Have had a lung transplant 4. Be using nebulised hypertonic saline concurrently or in the 2 weeks prior to visit 1 5. Have had a significant episode of haemoptysis (>60 mL) in the three months prior to enrolment 6. Have had a myocardial infarction in the three months prior to enrolment 7. Have had a cerebral vascular accident in the three months prior to enrolment 8. Have had major ocular surgery in the three months prior to enrolment 9. Have had major abdominal, chest or brain surgery in the three months prior to enrolment 10. Have a known cerebral, aortic or abdominal aneurysm 11. Be breast feeding or pregnant, or plan to become pregnant while in the study 12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only) 13. Be participating in another investigative drug study, parallel to, or within 4 weeks of study entry 14. Have a known allergy to mannitol 15. Be using beta blockers 16. Have uncontrolled hypertension – systolic BP > 190 and or diastolic BP > 100 17. Have a condition or be in a situation which in the Investigator’s opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient’s participation in the study 18. Be ‘Aridol-MTT test positive’.
研究者
相似试验
进行中（未招募）
不适用
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-IEPharmaxis Pharmaceuticals Limited250
进行中（未招募）
1 期
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 14.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2006-004078-28-GBPharmaxis UK Limited250
进行中（未招募）
不适用
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 8.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-GBPharmaxis Pharmaceuticals Limited340
已完成
3 期
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy StudyCystic FibrosisNCT00446680Syntara340
已完成
不适用
Inhaled mannitol improves sputum clearance in intubated patientsACTRN12609000145202A/Prof Paul Phipps25